Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.
IPO Year: 2018
Exchange: NASDAQ
Website: gritstonebio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 2/28/2024 | $4.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | Outperform | Evercore ISI | |
| 3/28/2023 | $8.00 | Buy | B. Riley Securities |
| 10/31/2022 | $6.00 | Overweight | Piper Sandler |
| 8/22/2022 | $2.00 | Neutral → Sell | Goldman |
| 12/15/2021 | $15.00 | Neutral | Goldman |
| 10/15/2021 | $20.00 | Buy | BTIG Research |